【摘要】 目的评价法罗培南治疗的呼吸、泌尿系统细菌感染性疾病的疗效和安全性。方法采用多中心随机单盲阳性药平行对照试验方法。共入选有效病例226例,试验组114例,对照组112例。试验组予法罗培南口服,每次200mg,每日3次;对照组予头孢泊肟口服,每次100mg,每日2次,疗程均为7～14d。比较2组临床疗效及不良反应。结果试验组与对照组临床痊愈率分别为83.3%和80.4%,有效率分别为95.6%和95.5%,2组临床疗效比较无显著差异(P>0.05)。细菌清除率均为99%,组间无显著差异(P>0.05)。药物不良反应发生率分别为6.8%和6.1%,组间差异无显著意义(P>0.05)。结论法罗培南治疗临床常见急性细菌感染性疾病安全、有效。更多还原

【Abstract】 AIM To evaluate the efficacy and safety of faropenem in the treatment of respiratory and urinary bacterial infections.METHODS A single blind randomized,parallel controlled,multicenter clinical trial was carried out.In the study,114 patients were enrolled in trial group(faropenem 200 mg,3 times daily) and another 112 patients enrolled in control group(cefpodoxime 100 mg,2 times daily) ,with a course of 7 to 14 days for both groups.The clinical efficacy and safety together with adverse reactions were investigated and compared.RESULTS The cure rates and total effective rates for the trial and control groups were 83.3%,80.4% 95.6%,and 95.5%,respectively.The bacterial clearance rates were both 99%,and the incidences of drug adverse reaction were 6.8% and 6.1%,respectively.There were no statistically significant differences betweenthe results of both groups(P > 0.05) .CONCLUSION Faropenem is effective and safe for treating acute bacterial infection.更多还原